Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 125

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 125
---
 | ​ | ​             | November 1, 2024   | ​ | ​             | January 1, 2025    |     |             6 | % |                    |    400 | ​ |                |    400 |
| Amantes LLC              | ​ | ​             | November 27, 2024  | ​ | ​             | January 26, 2025   |     |             6 | % |                    |    300 | ​ |                |    300 |
| Amantes LLC              | ​ | ​             | January 2, 2025    | ​ | ​             | March 1, 2025      |     |             6 | % |                    |    250 | ​ |                |    250 |
| Amantes LLC              | ​ | ​             | January 23, 2025   | ​ | ​             | March 22, 2025     |     |             6 | % |                    |     50 | ​ |                |     50 |
| Total                    | ​ | ​             | ​                  | ​ | ​             | ​                  |     |               | ​ | $                  | 23,686 | ​ | $              | 20,686 |

Subsequent to March 31, 2025, we borrowed a total of $3.6 million from Prophase, a related party of the Company due to having common executives, pursuant to loan agreements between the Company and Prophase (the “Prophase April 2025 Loans”). The Prophase 2025 Loans bear interest at 6% per annum and are due in May 2025. Given that Prophase is a related party, the Company and Prophase have mutually agreed to defer repayment of the past due loans until a time that is mutually agreed upon by both parties. As the Company’s loans are with related parties, the Company and its related parties have mutually agreed to defer repayment of the past due loans until the completion of the Business Combination. As such, the Company deems that it is not in default of its loan agreements. Such amounts were still due and payable subsequent to the closing of the Business Combination.

82

We therefore anticipate that we will need substantial additional funding in connection with our continuing operations. We intend to devote most of the net proceeds from the Business Combination to clinical development of our product candidates, repaying our debt, our public company compliance costs and certain of the milestone payments under the CAR-T License